Skip to main content

Table 3 Observed responses from randomized runs in the Box–Behnken design

From: Application of Box–Behnken design and desirability function in the development and optimization of self-nanoemulsifying drug delivery system for enhanced dissolution of ezetimibe

Run Formula-tion code Globule size (nm)
(Y1)
PDI Zeta potential (mV) Transmittance (%)
(Y2)
Self-emulsification time (sec)
(Y3)
% drug release after 5 min
(Y4)
% drug release after 40 min
(Y5)
1 F1 55.3 ± 3.08 0.275 − 25.5 ± 6.46 100.1 ± 3.46 90 ± 1.33 38.17 ± 2.64 70.54 ± 3.54
2 F2 45.7 ± 2.89 0.287 − 23.9 ± 5.81 100.8 ± 2.94 82 ± 2.54 40.27 ± 2.98 75.62 ± 3.02
3 F3 102.1 ± 8.88 0.444 − 17 ± 4.73 93.8 ± 5.61 182 ± 4.67 32.22 ± 2.11 58.21 ± 2.14
4 F4 76.8 ± 3.65 0.298 − 22.9 ± 4.81 97.2 ± 4.32 145 ± 5.12 36.19 ± 2.14 66.72 ± 2.11
5 F5 55.8 ± 2.14 0.299 − 26.2 ± 3.35 100.3 ± 2.54 94 ± 3.31 39.85 ± 2.13 71.29 ± 2.56
6 F6 89.9 ± 3.57 0.302 − 18.3 ± 3.37 98.2 ± 2.15 170 ± 4.98 33.29 ± 1.97 60.16 ± 2.81
7 F7 81.83 ± 2.68 0.271 − 23.9 ± 6.38 98.5 ± 3.68 125 ± 4.41 34.09 ± 2.56 63.45 ± 2.49
8 F8 24.4 ± 2.07 0.247 − 26.4 ± 6.52 101.2 ± 1.97 55 ± 3.54 49.21 ± 2.99 95.27 ± 2.38
9 F9 76.2 ± 3.02 0.315 − 24 ± 5.15 97.4 ± 2.41 118 ± 2.63 34.62 ± 3.03 65.81 ± 2.62
10 F10 31.8 ± 2.15 0.276 − 26.3 ± 2.48 99.3 ± 3.15 67 ± 1.14 43.18 ± 2.91 84.21 ± 2.51
11 F11 56 ± 3.27 0.322 − 26.1 ± 3.64 100.2 ± 4.81 97 ± 1.89 39.13 ± 2.10 70.85 ± 1.45
12 F12 32.2 ± 2.08 0.259 − 16.6 ± 3.52 98.1 ± 3.12 68 ± 2.14 45.69 ± 2.13 91.23 ± 3.05
13 F13 38.8 ± 2.45 0.268 − 27.1 ± 5.88 97.9 ± 3.65 85 ± 3.05 41.56 ± 1.95 78.26 ± 2.33
14 F14 63.91 ± 3.91 0.308 − 11.2 ± 3.52 97.6 ± 2.88 105 ± 2.54 37.02 ± 3.13 68.61 ± 2.84
15 F15 38.4 ± 2.31 0.302 − 21.7 ± 5.08 98.7 ± 2.69 70 ± 2.96 42.17 ± 2.52 82.24 ± 2.08